



THE HOUSE OF REPRESENTATIVES

STANDING COMMITTEE ON HEALTH, AGED CARE AND SPORT

Inquiry into approval processes for new drugs and novel medical technologies in Australia

PUBLIC HEARING
Friday 23 April 2021

Flinders Room
Mantra on Russell, 222 Russell Street, Melbourne

Time	Witness
9.00 am	Roundtable - Pharma: UCB Australia Ms Selina Clifford, Head of Neurology & Country Lead Gilead Sciences Ms Jaime McCoy, General Manager Bristol-Myers Squibb Mr Neil MacGregor, Managing Director
10.00 am	Research/Industry: Monash Institute of Medical Engineering (MIME) Prof John Forsythe, Co-Director Prof Helena Teede, Co-Director Research Australia Mr Greg Mullins, Head of Policy
11.00 am	Break
11.15 am	Roundtable - Clinical trials: Melbourne Academic Centre for Health (MACH) Prof Andrew Davidson, Medical Director, Melbourne Children's Trials Centre and Chair Clinical Trials Committee University of Melbourne (member of MACH) Dr Heather St John, Director, Research and Enterprise Development; Research, Innovation and Commercialisation Melbourne's Children's Campus Prof Andrew Davidson, Medical Director, Melbourne Children's Trials Centre White Coats Foundation Mrs Christine Zahren, Director
12.30 pm	Break

1.30 pm	<p>Roundtable - Patient Advocacy Groups: Victorian Comprehensive Cancer Centre Prof Grant McArthur, Executive Director</p> <p>Melanoma & Skin Cancer Advocacy Network (MSCAN) Ms Tamara Dawson, Director</p> <p>Ovarian Cancer Australia Ms Jane Hill, Chief Executive</p> <p>NeuroEndocrine Cancer Australia Ms Simone Leyden, Chief Executive Officer and Co-founder</p>
2.30 pm	<p>Roundtable - Patient Advocacy Groups: Leukaemia Foundation Mr Tim Murphy, General Manager, Blood Cancer Partnerships</p> <p>Blood Cancer Taskforce Prof John Seymour, Co-Chair</p> <p>Haematology Society of ANZ and Leukaemia and Lymphoma Group Ms Delaine Smith, Chief Executive Officer</p> <p>Haemophilia Foundation Australia Ms Sharon Caris, Executive Director</p> <p>Australian and New Zealand Children's Haematology/Oncology Group Acting Prof Jordan Hansford, Director, CNS Group Chair</p>
3.30 pm	Close